{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T06:47:21Z","timestamp":1792392441069,"version":"4.4.0"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG079307"],"award-info":[{"award-number":["R01AG079307"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG072291"],"award-info":[{"award-number":["R01AG072291"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA307311"],"award-info":[{"award-number":["R01CA307311"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA258778"],"award-info":[{"award-number":["R01CA258778"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.tips.2026.09.009","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:08:43Z","timestamp":1792213723000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Engineering monocytes and macrophages for therapeutic control"],"prefix":"10.1016","author":[{"given":"Yunzhu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingye","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2026.09.009_bb0005","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41577-026-01296-0","article-title":"Pathophysiological roles of monocytes and macrophages in cancer","volume":"26","author":"Ji","year":"2026","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tips.2026.09.009_bb0010","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41577-025-01231-9","article-title":"Phagocytosis: a process that shapes immune responses to engulfed meals","volume":"26","author":"Li","year":"2026","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tips.2026.09.009_bb0015","doi-asserted-by":"crossref","first-page":"42706","DOI":"10.31083\/FBL42706","article-title":"Macrophages and tissue homeostasis: from physiological functions to disease onset","volume":"30","author":"Li","year":"2025","journal-title":"Front. Biosci. (Landmark Ed)"},{"key":"10.1016\/j.tips.2026.09.009_bb0020","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.tips.2026.02.002","article-title":"Macrophage heterogeneity and plasticity: mechanism and therapeutics","volume":"47","author":"Li","year":"2026","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.tips.2026.09.009_bb0025","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.tips.2026.09.009_bb0030","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/j.ccell.2025.06.014","article-title":"Engineering myeloid cells for cancer immunotherapy","volume":"43","author":"Chen","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tips.2026.09.009_bb0035","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202312038","article-title":"Oxidized mRNA lipid nanoparticles for in situ chimeric antigen receptor monocyte engineering","volume":"34","author":"Mukalel","year":"2024","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.tips.2026.09.009_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1501365","article-title":"In Vivo programmed myeloid cells expressing novel chimeric antigen receptors show potent anti-tumor activity in preclinical solid tumor models","volume":"15","author":"Argueta","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2026.09.009_bb0045","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/s41584-025-01279-w","article-title":"Dynamic macrophage phenotypes in autoimmune and inflammatory rheumatic diseases","volume":"21","author":"Cutolo","year":"2025","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.tips.2026.09.009_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1732718","article-title":"Macrophage polarization: molecular mechanisms, disease implications, and targeted therapeutic strategies","volume":"16","author":"Ji","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2026.09.009_bb0055","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","article-title":"CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial","volume":"31","author":"Reiss","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2026.09.009_bb0060","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2682","article-title":"A phase 1, first-in-human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2-overexpressing solid tumors","volume":"42","author":"Abdou","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.tips.2026.09.009_bb0065","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41590-023-01687-8","article-title":"A second-generation M1-polarized CAR macrophage with antitumor efficacy","volume":"25","author":"Lei","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tips.2026.09.009_bb0070","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/s41551-025-01387-8","article-title":"Targeting inflammation with chimeric antigen receptor macrophages using a signal switch","volume":"9","author":"Cao","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.tips.2026.09.009_bb0075","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2519819123","article-title":"Synthetic SIGLEC9-based chimeric switch receptor augments the efficacy of CAR macrophages against glioblastoma","volume":"123","author":"Fu","year":"2026","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2026.09.009_bb0080","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011057","article-title":"Macrophages expressing chimeric cytokine receptors have an inflammatory phenotype and antitumoral activity upon IL-10 or TGF\u03b2 stimulation","volume":"13","author":"Traxel","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.tips.2026.09.009_bb0085","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1158\/1078-0432.CCR-26-0481","article-title":"Targeting CD24 activates macrophages to reduce tumor burden in preclinical models of solid tumors","volume":"32","author":"Faget","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tips.2026.09.009_bb0090","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41577-024-01081-x","article-title":"Induced pluripotent stem cell-derived macrophages as a platform for modelling human disease","volume":"25","author":"Tiwari","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tips.2026.09.009_bb0095","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.1038\/s41467-023-41470-9","article-title":"Metabolic reprogramming via ACOD1 depletion enhances function of human induced pluripotent stem cell-derived CAR-macrophages in solid tumors","volume":"14","author":"Wang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2026.09.009_bb0100","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41698-025-01170-7","article-title":"CAR-macrophages in solid tumors: promise, progress, and prospects","volume":"9","author":"Alrehaili","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.tips.2026.09.009_bb0105","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1186\/s12967-025-07115-9","article-title":"New power in cancer immunotherapy: the rise of chimeric antigen receptor macrophage (CAR-M)","volume":"23","author":"Jing","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.tips.2026.09.009_bb0110","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13045-026-01792-9","article-title":"Optimizing next-generation CAR-macrophages against solid tumors: challenges and potential strategies","volume":"19","author":"Chen","year":"2026","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.tips.2026.09.009_bb0115","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3724\/abbs.2026017","article-title":"CAR-macrophages: a new chapter in cancer immunotherapy","volume":"58","author":"Tang","year":"2026","journal-title":"ABBS (Shanghai)"},{"key":"10.1016\/j.tips.2026.09.009_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.tips.2026.02.009","article-title":"Programmable CAR immunotherapies for neurodegenerative proteinopathies","author":"Pesce","year":"2026","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.tips.2026.09.009_bb0125","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jare.2025.01.004","article-title":"Exploring CAR-macrophages in non-tumor diseases: therapeutic potential beyond cancer","volume":"77","author":"Chen","year":"2025","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.tips.2026.09.009_bb0130","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ccell.2026.01.020","article-title":"Macrophages: targets for next-generation cancer immunotherapy","volume":"44","author":"Sun","year":"2026","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tips.2026.09.009_bb0135","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.263833","article-title":"Phagocytosis at a glance","volume":"138","author":"Depierre","year":"2025","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.tips.2026.09.009_bb0140","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41568-025-00893-w","article-title":"Targeting phagocytosis checkpoints for cancer immunotherapy","volume":"26","author":"Veillette","year":"2026","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.tips.2026.09.009_bb0145","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-024-01635-5","article-title":"A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy","volume":"17","author":"Li","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.tips.2026.09.009_bb0150","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS4218","article-title":"A first-in-human study of MT-303, an innovative in vivo mRNA chimeric antigen receptor (CAR) therapy targeting GPC3, in adults with hepatocellular carcinoma","volume":"43","author":"Humphries","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tips.2026.09.009_bb0155","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41416-023-02319-6","article-title":"Efficacy evaluation of chimeric antigen receptor-modified human peritoneal macrophages in the treatment of gastric cancer","volume":"129","author":"Dong","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.tips.2026.09.009_bb0160","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41467-024-55770-1","article-title":"Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models","volume":"16","author":"Pierini","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2026.09.009_bb0165","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1186\/s12967-023-04479-8","article-title":"The application of HER2 and CD47 CAR-macrophage in ovarian cancer","volume":"21","author":"Chen","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.tips.2026.09.009_bb0170","article-title":"GPC3-targeted CAR-M cells exhibit potent antitumor activity against hepatocellular carcinoma","volume":"39","author":"Guan","year":"2024","journal-title":"Biochem. Biophys. Rep."},{"key":"10.1016\/j.tips.2026.09.009_bb0180","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1146\/annurev-cellbio-101323-121655","article-title":"The perils and promise of cellular cannibalism in development, homeostasis, and disease","volume":"41","author":"Rodriguez","year":"2025","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.tips.2026.09.009_bb0185","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13045-025-01743-w","article-title":"PSMA-targeted CAR-macrophages drive glycolytic reprogramming for enhanced prostate cancer immunotherapy","volume":"18","author":"Xu","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.tips.2026.09.009_bb0190","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12943-024-02184-8","article-title":"Chimeric antigen receptor macrophages targeting c-MET(CAR-M-c-MET) inhibit pancreatic cancer progression and improve cytotoxic chemotherapeutic efficacy","volume":"23","author":"Zheng","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.tips.2026.09.009_bb0195","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/s41388-025-03332-0","article-title":"Human CSPG4-targeting CAR-macrophages inhibit melanoma growth","volume":"44","author":"Greiner","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.tips.2026.09.009_bb0205","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1186\/s12967-026-07897-6","article-title":"Targeting GPA33 with CAR-macrophages: a novel immunotherapeutic approach for colorectal cancer","volume":"24","author":"Wang","year":"2026","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.tips.2026.09.009_bb0210","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1783851","article-title":"Development and characterization of chimeric antigen receptor macrophages for amyloid clearance","volume":"17","author":"Balachandran","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2026.09.009_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2026.114710","article-title":"Anti-CLEC7A nanobody in situ engineering promotes amyloid-\u03b2 oligomers clearance by CAR-microglia to alleviate Alzheimer\u2019s disease pathology in mice","volume":"392","author":"Yan","year":"2026","journal-title":"J. Control. Release"},{"key":"10.1016\/j.tips.2026.09.009_bb0220","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/1061186X.2024.2417012","article-title":"Emerging advances in nano-biomaterial assisted amyloid beta chimeric antigen receptor macrophages (CAR-M) therapy: reducing plaque burden in Alzheimer\u2019s disease","volume":"33","author":"Kushwaha","year":"2025","journal-title":"J. Drug Target."},{"key":"10.1016\/j.tips.2026.09.009_bb0225","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41420-024-02247-1","article-title":"Macrophages in organ fibrosis: from pathogenesis to therapeutic targets","volume":"10","author":"Jiang","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.tips.2026.09.009_bb0230","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1146\/annurev-pathmechdis-042624-114332","article-title":"Basic microglial functions and how they go awry in neurodegenerative disease","volume":"21","author":"McKinney","year":"2026","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.tips.2026.09.009_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113888","article-title":"In vivo FAP-CAR macrophages enhance chemotherapy and immunotherapy against pancreatic cancer by removing the fibrosis barrier","volume":"384","author":"Wang","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.tips.2026.09.009_bb0240","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1038\/s41467-025-59326-9","article-title":"CAR macrophages with built-in CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentation","volume":"16","author":"Chen","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2026.09.009_bb0245","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1186\/s12964-025-02548-7","article-title":"CD86 costimulation enhances the antitumor activity of NKG2D CAR-macrophages and synergizes with anti-PD-L1 therapy to suppress prostate cancer progression","volume":"23","author":"Ibrahim","year":"2025","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.tips.2026.09.009_bb0250","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12943-025-02538-w","article-title":"Synergistic innate-adaptive immunity by NKG2D-specific CAR-macrophages drives durable remission in hepatocellular carcinoma","volume":"25","author":"Zhao","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.tips.2026.09.009_bb0255","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.stem.2024.03.018","article-title":"Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer","volume":"31","author":"Shah","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.tips.2026.09.009_bb0260","doi-asserted-by":"crossref","first-page":"7166","DOI":"10.1038\/s41467-025-62506-2","article-title":"Lung metastasis and recurrence is mitigated by CAR macrophages, in-situ-generated from mRNA delivered by small extracellular vesicles","volume":"16","author":"Xiao","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2026.09.009_bb0265","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/s41467-025-68033-4","article-title":"Viscoelastic hydrogel primed CAR-macrophage for pulmonary fibrosis treatment","volume":"17","author":"Zhang","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2026.09.009_bb0270","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.175015","article-title":"Chimeric antigen receptor macrophages target and resorb amyloid plaques","volume":"9","author":"Kim","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.tips.2026.09.009_bb0275","article-title":"Microneedle delivery of CAR-M-like engineered macrophages alleviates intervertebral disc degeneration through enhanced efferocytosis capacity","volume":"6","author":"Zhou","year":"2026","journal-title":"Cell. Rep. Med."},{"key":"10.1016\/j.tips.2026.09.009_bb0280","article-title":"Photoresponsive vaccine-like CAR-M system with high-efficiency central immune regulation for inflammation-related depression","volume":"34","author":"Liu","year":"2022","journal-title":"Adv. Mater."},{"key":"10.1016\/j.tips.2026.09.009_bb0290","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.36688","article-title":"Chimeric antigen receptors that trigger phagocytosis","volume":"7","author":"Morrissey","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.tips.2026.09.009_bb0295","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.3390\/cells11223692","article-title":"CAR-macrophages and CAR-T cells synergistically kill tumor cells in vitro","volume":"11","author":"Liu","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.tips.2026.09.009_bb0300","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1007\/s00262-023-03490-8","article-title":"Chimeric antigen receptor macrophages activated through TLR4 or IFN-\u03b3 receptors suppress breast cancer growth by targeting VEGFR2","volume":"72","author":"Duan","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.tips.2026.09.009_bb0305","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41577-023-00921-6","article-title":"Cell death by phagocytosis","volume":"24","author":"Brown","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tips.2026.09.009_bb0310","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202502034","article-title":"Target cell adhesion limits macrophage phagocytosis and promotes trogocytosis","volume":"224","author":"Rollins","year":"2025","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.tips.2026.09.009_bb0315","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/stem.3449","article-title":"Human induced pluripotent stem cell-derived macrophages ameliorate liver fibrosis","volume":"39","author":"Pouyanfard","year":"2021","journal-title":"Stem Cells"},{"key":"10.1016\/j.tips.2026.09.009_bb0320","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.7150\/ijbs.127434","article-title":"Identification of trogocytosis as an essential limitation factor in hPSC-derived CAR macrophages","volume":"22","author":"Kang","year":"2026","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.tips.2026.09.009_bb0325","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1182\/blood.2020005571","article-title":"Macrophage hypophagia as a mechanism of innate immune exhaustion in mAb-induced cell clearance","volume":"136","author":"Pinney","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.tips.2026.09.009_bb0330","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.263539","article-title":"Depletion of endomembrane reservoirs drives phagocytic appetite exhaustion in macrophages","volume":"138","author":"Fountain","year":"2025","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.tips.2026.09.009_bb0335","article-title":"SIRP\u03b1 ablated iPSC-derived macrophages resist hypophagia and enhance mAb-dependent and CAR-mediated cytotoxicity of solid tumors","volume":"34","author":"Smith","year":"2026","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.tips.2026.09.009_bb0340","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202502206","article-title":"CD47 inhibits phagocytosis through Vav dephosphorylation","volume":"224","author":"Miller","year":"2025","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.tips.2026.09.009_bb0345","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2310221120","article-title":"Hyperactive Rac stimulates cannibalism of living target cells and enhances CAR-M-mediated cancer cell killing","volume":"120","author":"Mishra","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2026.09.009_bb0350","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001356","article-title":"Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses","volume":"8","author":"Brempelis","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.tips.2026.09.009_bb0355","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1039\/D5NR03762J","article-title":"In situ programming of CAR-macrophages via a polyplex nanomaterial and STING activation for triple-negative breast cancer immunotherapy","volume":"18","author":"Siddiqui","year":"2026","journal-title":"Nanoscale"},{"key":"10.1016\/j.tips.2026.09.009_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114720","article-title":"Advancing immunotherapy with innovations in CAR-M engineering for cancer treatment","volume":"156","author":"Lee","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.tips.2026.09.009_bb0365","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adl2388","article-title":"Plasma membrane abundance dictates phagocytic capacity and functional cross-talk in myeloid cells","volume":"9","author":"Winer","year":"2024","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.tips.2026.09.009_bb0370","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.3389\/fimmu.2020.01097","article-title":"Physical constraints and forces involved in phagocytosis","volume":"11","author":"Jaumouill\u00e9","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2026.09.009_bb0375","first-page":"392","article-title":"Metabolic engineering of SLC38A2 reprograms glutamine utilization and enhances CAR-macrophage antitumor function in solid tumors","volume":"23","author":"Liu","year":"2026","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.tips.2026.09.009_bb0380","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.tibtech.2026.02.011","article-title":"Breaking the immunosuppressive barrier: an armored CAR-M biotechnology with the original M1 phenotype dominance rescues antitumor immunity","volume":"44","author":"Du","year":"2026","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.tips.2026.09.009_bb0385","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/s41419-024-07267-4","article-title":"Inhibition of furin in CAR macrophages directs them toward a proinflammatory phenotype and enhances their antitumor activities","volume":"15","author":"Ziane-Chaouche","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.tips.2026.09.009_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2024.103217","article-title":"Protocol for differentiation of monocytes and macrophages from human induced pluripotent stem cells","volume":"5","author":"Emmerich","year":"2024","journal-title":"STAR Protoc."},{"key":"10.1016\/j.tips.2026.09.009_bb0395","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.stemcr.2021.05.018","article-title":"Differentiation of human induced pluripotent stem cells to authentic macrophages using a defined, serum-free, open-source medium","volume":"16","author":"Vaughan-Jackson","year":"2021","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.tips.2026.09.009_bb0400","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.stemcr.2022.12.012","article-title":"Generation of anti-GD2 CAR macrophages from human pluripotent stem cells for cancer immunotherapies","volume":"18","author":"Zhang","year":"2023","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.tips.2026.09.009_bb0405","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/genbio.2021.0010","article-title":"Genome editing of pluripotent stem cells for adoptive and regenerative cell therapies","volume":"1","author":"Blassberg","year":"2022","journal-title":"GEN Biotechnol."},{"key":"10.1016\/j.tips.2026.09.009_bb0410","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41587-019-0016-3","article-title":"Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients","volume":"37","author":"Deuse","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.tips.2026.09.009_bb0415","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.3860","article-title":"HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells","volume":"35","author":"Gornalusse","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.tips.2026.09.009_bb0420","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12967-023-04061-2","article-title":"M1 polarization enhances the antitumor activity of chimeric antigen receptor macrophages in solid tumors","volume":"21","author":"Huo","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.tips.2026.09.009_bb2005","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.immuni.2024.04.019","article-title":"Classical monocyte ontogeny dictates their functions and fates as tissue macrophages","volume":"57","author":"Trzebanski","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.tips.2026.09.009_bb2010","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/s41467-024-46076-3","article-title":"Intestinal stroma guides monocyte differentiation to macrophages through GM-CSF","volume":"15","author":"Kvedaraite","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2026.09.009_bb2015","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/s41467-024-46148-4","article-title":"Single-cell transcriptomics identifies the differentiation trajectory from inflammatory monocytes to pro-resolving macrophages in a mouse skin allergy model","volume":"15","author":"Miyake","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2026.09.009_bb2020","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2026.09.009_bb2025","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ymthe.2016.11.006","article-title":"Selective blockade of the ubiquitous checkpoint receptor CD47 is enabled by dual-targeting bispecific antibodies","volume":"25","author":"Dheilly","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tips.2026.09.009_bb2030","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nrd.2016.245","article-title":"Induced pluripotent stem cell technology: a decade of progress","volume":"16","author":"Shi","year":"2017","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614726002531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614726002531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T06:32:30Z","timestamp":1792391550000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614726002531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":87,"alternative-id":["S0165614726002531"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2026.09.009","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineering monocytes and macrophages for therapeutic control","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2026.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}